Our data suggests an association between high separase activity, residual BCR-ABL1 gene expression, and enhanced proliferative capacity in hematopoietic cells within the leukemic niche of TKI-treated chronic phase CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.